EULAR 2008

skip to the content

MabThera Rituximab – B Cell Therapy, Lasting Success

EULAR 2008

Here you can download the EULAR 2008 media materials

Press Release

New evidence shows MabThera® is more effective than a second TNF inhibitor in rheumatoid arthritis patients who have interrupted anti-TNF therapy due to lack of efficacy

Backgrounders

MabThera in rheumatoid arthritis

Key Abstracts

A. Finckh et al.
Which subgroup of rheumatoid arthritis patients benefit most from switching to Rituximab versus alternative anti-TNF agents previous failure to anit-TNF agent?

S. Cohen, et al.
Continued inhibition of structural damage in rheumatoid arthritis patients treated with Rituximab at 2 years: REFLEX Study

A. J. K. Ostor, et al.
Patient preference for Rituximab as a treatment for rheumatoid arthritis: A study using discrete choice analysis

Video clips and high resolution stills relating to MabThera and rheumatoid arthritis

Image library featuring: diagnosis and symptoms, joint effects, lifestyle, role of B cells and rituximab MOA

Legal Statement
Sitemap
Privacy Policy
Roche.com
© 2009 F. Hoffmann-La Roche Ltd. The site is intended for non US physicians and scientific media only.Prescribing information, pricing and indications for MabThera may differ from country to country.Please consult your local Roche company for such information you may be interested in.